Navidea Biopharmaceuticals Posts Lymphoseek®NDA Update to Company Website
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents, today posted on its website an update to the status of the Lymphoseek NDA review. The web access to the statement can be found on the Navidea Investor page at: http://phx.corporate-ir.net/phoenix.zhtml?c=68527&p=irol-nda.
Brent Larson, Sr. VP & CFO
KEYWORDS: United States North America Ohio
The article Navidea Biopharmaceuticals Posts Lymphoseek® NDA Update to Company Website originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.